SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Follow-up) — Sonny Liston

PatientSonny Liston
Date of birth1989-05-08
IdentifiersMRN HR-BX007-SYN; SSN (made up) 000-07-8853
Document date2026-09-22
AuthorMalcolm Achebe-Whitford, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review of blood pressure and drinking. [S]

History of Present Illness

Sonny Liston returns two weeks after a cold, for which he stopped an over-the-counter decongestant; his home readings came back down within two days and have averaged 124/78 mmHg over the past week. He takes amlodipine 10 mg and valsartan 160 mg and naltrexone 50 mg each morning. Mild ankle swelling after long runs in the heat goes by morning. He drinks three or four drinks on one or two evenings a week and has not had more than four on any day since starting naltrexone; the urge to keep going is much weaker. He saw the dentist about his molar. He wants to start sparring hard again. No thoughts of suicide. [S]

ElementDetail
Home readingsAverage 124/78 mmHg
Liver testsAST 31, ALT 30, GGT 54 U/L
AUDIT-C4
Vaccine todaySecond hepatitis B dose

Review of Systems

SystemResultFinding
CardiovascularPositiveMild ankle swelling after long runs, gone by morning; no chest pain or palpitations
Ears, nose, mouth, and throatNegativeCold symptoms gone
GastrointestinalNegativeNo nausea on naltrexone
PsychiatricNegativeMood good; no thoughts of suicide

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg and valsartan 160 mg combined oral tablet, one tablet each morningOne tablet each morningOral route2026-06-23 to 2026-07-21completedS
Amlodipine 10 mg and valsartan 160 mg combined oral tablet, one tablet each morningOne tablet each morningOral route2026-07-21activeS
Naltrexone 50 mg oral tablet, one tablet each morningOne tablet each morningOral route2026-07-21activeS
Pseudoephedrine 30 mg oral tablet, bought over the counter as a cold tablet, two tablets up to four times a dayTwo tablets up to four times a dayOral route2026-09-05 to 2026-09-08stoppedS
Acetaminophen 500 mg oral tablet, one or two tablets every six hours as needed for aches, no more than four tablets (2 g) a day because he drinksOne or two tablets every six hours as needed; no more than four tablets a dayOral route2026-09-08 to 2026-09-15completedS
Saline nasal spray 0.65%, two sprays in each nostril as neededTwo sprays in each nostril as neededNasal route2026-09-08 to 2026-09-15completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-22Body height185cmS
2026-09-22Body weight97.2kgS
2026-09-22Body mass index (BMI) [Ratio]28.4kg/m2S
2026-09-22Systolic blood pressure126mm[Hg]S
2026-09-22Diastolic blood pressure78mm[Hg]S
2026-09-22Heart rate56/minS
2026-09-22Respiratory rate14/minS
2026-09-22Body temperature36.6CelS
2026-09-22Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-22Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L10-40 U/LNormalS
2026-09-22Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-56 U/LNormalS
2026-09-22Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma54U/L8-61 U/LNormalS
2026-09-22Total score [AUDIT-C]4{score}S

Physical Exam

Vital signs recorded on 2026-09-22; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 126/78 mmHg (average of two); pulse 56; weight 97.2 kg
CardiovascularRegular rhythm; trace ankle edema

Problems

ProblemClinical statusVerificationCodeProvenance
High blood pressure readings at a first visit (154/98 mmHg, average of two readings with a large cuff), without a diagnosis of hypertension; out-of-office confirmation neededresolvedconfirmed R03.0S — Synthetic presenting finding; resolved into the diagnosis at the consultation visit when ambulatory monitoring confirmed hypertension.
Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (daytime average 146/94 mmHg, nighttime 132/84 mmHg), with mild concentric left ventricular hypertrophy on echocardiography and normal kidney function and urine albuminactiveconfirmed I10S — Synthetic modern diagnosis; no hypertension is documented in his life.
Alcohol use disorder, moderate (four DSM-5-TR criteria: drinking more than intended, unsuccessful efforts to cut down, craving, and continued drinking despite its effect on his training, blood pressure and liver tests); AUDIT 16activeconfirmed F10.20S — Synthetic modern diagnosis by interview, anchored to the description of heavy drinking; not a historical diagnosis.
Personal history of physical abuse in childhood (beaten regularly by his father), with heavy field work from the age of eightactiveconfirmed Z62.810S — Synthetic coding of the documented childhood history; physical abuse only.
Does not read or write (no schooling as a child); prefers spoken explanations, pictures and demonstrationsactiveconfirmed Z55.0S — Synthetic coding of the documented literacy, recorded so that care is adapted.
Acute viral upper respiratory infection (common cold) for four days, with blood pressure raised to 158/98 mmHg by an over-the-counter pseudoephedrine cold tablet he could not read the label of; resolvedresolvedconfirmed J06.9S — Synthetic acute illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationOffice blood pressure (seated, large cuff, average of two readings), weight and BMI, heart soundsEvery visitCompleted today126/78 mmHg; weight 97.2 kg
ExaminationOut-of-office blood pressure (ambulatory or home monitoring)At diagnosis and after each treatment changeCompleted todayHome average 124/78 mmHg by voice message
LaboratoryPotassium, creatinine and eGFRBaseline; two to four weeks after starting an ARB; then every six months on an ARBUp to datePotassium 4.4 and creatinine 1.1 two months ago; next in about four months
ExaminationFundoscopic examinationYearlyUp to dateNormal at the preventive visit
SurveyCardiovascular risk estimateYearlyUp to dateLow at the preventive visit; statin not indicated
Medication safetyAntihypertensive tolerance (ankle edema, dizziness) and adherence by teach-backEach follow-up and each dose changeCompleted todayTrace ankle edema after long runs; no dizziness; teach-back correct
ReferralFitness to compete (AHA/ACC athlete statement)At diagnosis and before returning to competitionCompleted todayControlled; letter to the commission physician for clearance
SurveyDrinking (AUDIT-C, drinks per week, drinking days)Every follow-up during treatment; full AUDIT at about four monthsCompleted todayAUDIT-C 4; about 7 drinks a week, no day above 4
LaboratoryLiver tests (AST, ALT, GGT)Baseline; about two months after starting naltrexone or cutting down; then as indicatedCompleted todayAST 31, ALT 30, GGT 54 U/L, two months after starting naltrexone
Medication safetyNaltrexone: nausea, liver tests, and opioid-blockade wallet cardEach follow-up after startingCompleted todayNo nausea; liver tests improving; carries the wallet card
SurveySuicide-risk review (structured questions) and safety planEvery visitCompleted todayNo thoughts of suicide
Self-managementHealth literacy: teach-back, picture card, read-aloud consent, voice remindersEvery visitCompleted todayTeach-back of the medicines to avoid correct; the pharmacist now reads labels to him

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, hypertension and depression monographs (2026); Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (Black HR, et al.) (2015); The Healthcare Professional's Core Resource on Alcohol (2026); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition (2024); Adult Immunization Schedule by Age (2026)

Follow-up: Four-month review in four weeks with the full AUDIT, GGT and PHQ-9, and the influenza vaccine. Call 988 or the clinic at any time if thoughts of suicide arise. Next scheduled visit 2026-10-20: four-month review: blood pressure at goal, AUDIT, and the plan ahead. [S]